Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Access to medicines and treatment news

Show

From To
Are 2 million bottles of PrEP an empty gesture?

Gilead should either commit to providing all the doses of PrEP required for everyone who would benefit or open the market up to a range of generic manufacturers.

Published
15 July 2019
From
The Lancet HIV
Insurance Will Soon Cover HIV Prevention, But Many People Who Need it Still Won't Have Access

When Corey Walsh began using the drug Truvada, the pills were free but the quarterly lab tests and doctors' visits cost almost $400.

Published
11 July 2019
From
Vice
Gilead fails to keep promise on access to lifesaving drug for people living with HIV

Pharmaceutical corporation Gilead promised to expand access at an affordable price to a drug for people with an HIV-related infection, cryptococcal meningitis. One year on, the drug is registered in only six developing countries and remains prohibitively expensive.

Published
01 July 2019
From
Médecins Sans Frontières
Desperate patients turn to buyers clubs

What do you do when the NHS won’t buy the treatment you need?

Published
25 June 2019
From
The Economist (free registration required)
Kenya: 69,000 newborns at risk due to ARVs shortage

Medical personnel at several public hospitals who spoke to the Nation on the condition of anonymity said the shortage began about four months ago. They said the situation is dire, and that if no intervention is made urgently, things could turn disastrous. The administration of ARVs to newborns without HIV is meant to reduce the risk of mother-to-child transmission (perinatal acquisition).

Published
24 June 2019
From
The Nation
For People With HIV, Health Coverage Is Improving

A new analysis finds that Obamacare has driven down the proportion of individuals without insurance.

Published
19 June 2019
From
Poz
PrEP reduces HIV infections by over 95% in US ‘real world’ study

A study of people prescribed pre-exposure prophylaxis (PrEP) over a four-year period at a large centre in Los Angeles has found that HIV incidence in people

Published
18 June 2019
By
Gus Cairns
Global ingredient shortage caused ARV stockouts

A worldwide shortage of an active pharmaceutical ingredient is the reason behind the anti-retroviral (ARV) medication shortfall across the country, the department of health confirmed. The anti-retroviral drug called Lamivudine is currently in short supply globally and this has affected ARVs that contain this ingredient.

Published
07 June 2019
From
Health-e
This drug could end HIV. Why hasn't it? (Podcast)

Dr. Robert Grant developed a treatment — a daily pill known as pre-exposure prophylaxis, or PrEP — that could stop the AIDS crisis. We look at why that hasn’t happened.

Published
06 June 2019
From
New York Times
WHO agrees watered-down resolution on transparency in drug costs

Countries at the World Health Organization agreed on Tuesday to push for clearer drug pricing, after watering down a draft resolution that would have also required pharmaceutical firms to disclose the cost of making medicines.

Published
02 June 2019
From
Reuters
← First12345...145Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.